Optimizing testing regimes for the detection of COVID-19 in children and older adults

被引:12
作者
Chauhan, Nidhi [1 ]
Soni, Shringika [1 ]
Jain, Utkarsh [1 ]
机构
[1] Amity Univ Uttar Pradesh, Amity Inst Nanotechnol AINT, Noida 201313, India
关键词
SARS-CoV-2; molecular diagnostics; immunodiagnostic; nanotechnology; sensors; point-of-care (POC) kits; children and older adults; RAPID DETECTION; SARS-COV; SARS-COV-2; ANTIBODY; SPIKE; PROTEIN; TARGET; RISK; ACE2;
D O I
10.1080/14737159.2021.1962708
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
Introduction: Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection is a major pandemic and continuously emerging due to unclear prognosis and unavailability of reliable detection tools. Older adults are more susceptible to COVID-19 than children showing mature Angiotensin-Converting Enzyme 2 (ACE2), low concentration of immune targets, and comorbid conditions. Several detection platforms have been commercialized to date and more are in pipeline, however, the rate of false-positive results and rapid mutation of SARS-CoV-2 is increasing. Additionally, physiological, and geographical variations of affected individuals are also calling for diagnostic methods optimization. Areas Covered: Extensive information related to the optimization and usefulness of SARS-CoV-2 diagnostic methods based on sensitivity and specificity as definitive and feasible investigative tools is discussed. Moreover, an option of combining laboratory diagnostic methods to improve diagnostic strategies is also proposed and discussed in the comparative section of optimization studies. Expert Opinion: The review article explains the importance of optimization strategies for SARS-CoV-2 detection in children and older adults. There are advancements in COVID-19 detection including CRISPR-based, electrochemical, and optical-based sensing systems. However, the lack of sufficient studies on a comparative evaluation of standardized SARS-CoV-2 diagnostic methods among children and older adults, limit the authentication of commercialized kits.
引用
收藏
页码:999 / 1016
页数:18
相关论文
共 136 条
  • [1] New SARS-CoV-2 Variants - Clinical, Public Health, and Vaccine Implications
    Abdool Karim, Salim S.
    de Oliveira, Tulio
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2021, 384 (19) : 1866 - 1868
  • [2] Effectiveness of the BNT162b2 Covid-19 Vaccine against the B.1.1.7 and B.1.351 Variants
    Abu-Raddad, Laith J.
    Chemaitelly, Hiam
    Butt, Adeel A.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2021, 385 (02) : 187 - 189
  • [3] COVID 19 infection: Pediatric perspectives
    Adeyinka, Adebayo
    Bailey, Keneisha
    Pierre, Louisdon
    Kondamudi, Noah
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF EMERGENCY PHYSICIANS OPEN, 2021, 2 (01)
  • [4] Molecular diagnostic technologies for COVID-19: Limitations and challenges
    Afzal, Adeel
    [J]. JOURNAL OF ADVANCED RESEARCH, 2020, 26 : 149 - 159
  • [5] Lung Injury in COVID-19-An Emerging Hypothesis
    Alharthy, Abdulrahman
    Faqihi, Fahad
    Memish, Ziad A.
    Karakitsos, Dimitrios
    [J]. ACS CHEMICAL NEUROSCIENCE, 2020, 11 (15): : 2156 - 2158
  • [6] Alizon S., 2021, EUROSURVEILLANCE, V26
  • [7] Clinical Characteristics and Outcomes Among COVID-19 Hospitalized Patients with Chronic Conditions: A Retrospective Single-Center Study
    Almalki, Ziyad Saeed
    Khan, Mohd Faiyaz
    Almazrou, Saja
    Alanazi, Abdullah Salah
    Iqbal, Muhammad Shahid
    Alqahtani, Abdulhadi
    Alghamdi, Saleh
    Alahmari, Abdullah K.
    [J]. JOURNAL OF MULTIDISCIPLINARY HEALTHCARE, 2020, 13 : 1089 - 1097
  • [8] Postvaccination COVID-19 among Healthcare Workers, Israel
    Amit, Sharon
    Beni, Sharon Alexsandra
    Biber, Asaf
    Grinberg, Amir
    Leshem, Eyal
    Regev-Yochay, Gili
    [J]. EMERGING INFECTIOUS DISEASES, 2021, 27 (04) : 1220 - 1222
  • [9] [Anonymous], 2021, EXPRESS NEWS SERV
  • [10] Arnaout Ramy, 2020, bioRxiv, DOI 10.1101/2020.06.02.131144